AAT see alpha-1 antitrypsin (AAT)
abdominal surgery, in patients with liver disease
  imaging techniques 338
  mortality rates 337, 340
abscess, hepatic 96–109
  amebic see amebic liver abscess
  pyogenic see pyogenic liver abscess
acetaminophen hepatotoxicity 281, 354
  alcohol usage and 128
  laboratory tests 285
  presentation 284
  prevention 282, 283
  prognostic criteria 27, 290
  severity classification 27
  treatment 28, 288
N-acetylcysteine see NAC (N-acetylcysteine) therapy
acute fatty liver of pregnancy (AFLP) 11, 289
  diagnosis 274–275, 275, 276
  etiology 272
  incidence/prevalence 272
  pathogenesis 272
  predictive/risk factors 272
  presentation 273, 274
  prognosis 278
  treatment 276, 277
acute kidney injury 248
  hepatic ischemia–reperfusion injury and 472
  see also hepatorenal syndrome (HRS)
acute liver failure (ALF) 280–293
  in children 291, 353–364
  classification 354
  clinical presentation 355–356
  definition 353
  diagnosis 355–359
    algorithm 356
  clinical 356–357
    differential 355, 355
  laboratory 357–359
  potential pitfalls/common errors 359
  etiologies 354
  images 364
  imaging techniques 359
  incidence/prevalence 354
  pathology/pathogenesis 354
  predictive/risk factors 354–355
  prognosis 363
  treatment 358–362, 361
  liver transplantation 360
  acute-on-chronic kidney disease 247, 248
  acute rejection 432, 437, 438, 440, 444–452
    classification 444
    clinical presentation 447
    definition 444
    diagnosis 446–448, 514
      algorithm 448
    clinical 447
      differential 446
      laboratory 447
      potential pitfalls/common errors 448
      etiology 445
      evidence 451
    histopathological features 446, 452
    imaging techniques 447
    incidence/prevalence 445
    indications for hospitalization 448
pathogenesis 445
predictive/risk factors 445
prevention 445–446
prognosis 451–452
screening 445, 454
severity classification 447
treatment 448–450, 450
algorithm 449
complications, prevention/management 450
effect on prognosis 451
acute tubular necrosis 247, 248
adefovir therapy, hepatitis B infection 46
resistance 49
adenoma, hepatic see hepatic adenomas
adherence
hepatitis C treatment 68
immunosuppressive therapy, pediatric liver transplant recipients 401
adjusted body weight (ABW) 348
adult services, transition to, pediatric liver transplant recipients 401
AFLP see acute fatty liver of pregnancy (AFLP)
AFP (alpha-fetoprotein) 371
African-Americans, hepatitis C treatment 74
AIDS cholangiopathy
clinical presentation 113, 114
definition 111
diagnosis 116
differential 162
etiology 112
incidence 112
pathogenesis 112
prognosis 118
treatment 116, 117
AIH see autoimmune hepatitis (AIH)
alanine aminotransferase (ALT) 3, 4–5, 365
 Elevated levels 3, 4, 6, 7
in children 366
levels in healthy children 365
albendazole therapy, hydatid cysts 329, 330
albumin 4, 369
liver function tests 4, 369
as plasma volume expander in large volume paracentesis 221
albumin therapy
hepatorenal syndrome 250, 251
spontaneous bacterial peritonitis 231, 233, 247
alcohol abuse
hepatitis C treatment and 75
screening 122, 124
alcohol consumption
acetaminophen toxicity and 128
low-risk vs. high-risk drinking limits 123
alcoholic hepatitis 120–131
clinical presentation 123
complications, prevention/management 127
definition 120
diagnosis 122–126
algorithm 125
clinical 123, 123–124
differential 35, 61, 123, 123, 126
imaging techniques 125
laboratory 6, 7, 26, 35, 124
pathologic features on liver biopsy 124–125, 131
potential pitfalls/common errors 125–126
economic impact 121
etiology/pathogenesis 121
guidelines 130
incidence/prevalence 120–121
indications for hospitalization 126
monitoring 129
predictive/risk factors 121–122
prevention 122
prognosis 129
risks of surgery 335, 337, 339, 342
severity classification 124
special populations 129
treatment 126–128, 127
algorithm 128
effect on prognosis 129
alcohol withdrawal 127
ALF see acute liver failure (ALF)
alkaline phosphatase (AP) 4
abnormal levels 4, 5, 7, 9
in children 367
allograft rejection
acute see acute rejection
chronic see chronic rejection
definition 444, 453
alpha-1 antitrypsin (AAT) 188
augmentation therapy 192
serum levels in alpha-1 antitrypsin deficiency 191
alpha-1 antitrypsin (AAT) deficiency 187–195
associated conditions 192
in children 190, 193
classification 187
clinical presentation 187, 190
definition 187
diagnosis 189–192
algorithm 191
clinical 190
differential 190
imaging techniques 191
laboratory 191
potential pitfalls/common errors 192
economic impact 188
etiology 188
follow-up tests and monitoring 194
guidelines 194
histopathology 191, 197
indications for hospitalization 192
liver disease 187, 188, 190
management 192, 193, 193
prognosis 194
pathology/pathogenesis 188
predictive/risk factors 188–189
pregnancy and 193
prevalence 188
prevention 189
prognosis 193–194
screening 189
treatment 192–193, 192
algorithm 193
alpha-fetoprotein (AFP) 371
ALT see alanine aminotransferase (ALT)
alveolar–arterial oxygen gradient 258
AMA (antimitochondrial antibodies), in primary biliary cirrhosis 152, 155
ambrisentan therapy, portopulmonary hypertension 268
amebic liver abscess (ALA) 96–103, 325
clinical presentation 98, 99
complications 97, 101
definition 96
anemic liver abscess (ALA) (cont’d)
diagnosis 98–100, 105, 328
clinical 98–99, 328
imaging techniques 100, 328
laboratory 99, 328
potential pitfalls/common errors 100
etiology 96, 326
incidence/prevalence 96, 326
indications for hospitalization 101
pathology/pathogenesis 96–97
predictive/risk factors 97
prevention 97–98
prognosis 103
severity classification 99
special populations 102
treatment 100–102, 102, 329, 330
effect on prognosis 103
amiloride therapy, cirrhotic ascites 219, 220
aminotransferases
abnormal levels in children 367
diagnostic algorithm 366
screening tests 367
see also alanine aminotransferase (ALT); aspartate aminotransferase (AST)
amiodarone hepatotoxicity, diagnosis 123
ammonia 372
elevated levels in children 372
in hepatic encephalopathy pathogenesis 236, 238
ammonium tetrathiomolybdate, Wilson disease treatment 182, 183
amoxicillin/clavulanic acid, spontaneous bacterial peritonitis treatment 231, 232
amylase, ascitic fluid 216
anemia, hepatitis C treatment side-effect 68, 71–72
anesthesia, hepatic effects 335
antibiotic prophylaxis
post-liver transplantation 433, 434, 496
for dental procedures 535
spontaneous bacterial peritonitis 229
antibiotic therapy
biliary infections 116
infection/sepsis in acute liver failure 287
portal hypertensive bleeding 201, 202
prophylactic see antibiotic prophylaxis
pyogenic liver abscess 107
spontaneous bacterial peritonitis 231–232
in children 386, 387
success rate 233
anti-coagulation therapy
Budd–Chiari syndrome 298, 298, 299, 300
portal vein thrombosis 305, 306
antifungal prophylaxis, post-liver transplantation 434, 496
antimitochondrial antibodies (AMA), in primary biliary cirrhosis 152, 155
antinuclear antibody (ANA), autoimmune hepatitis diagnosis 144, 146
antiretroviral liver toxicity 83, 83
antiretroviral therapy
HIV/HBV co-infected patients 80, 85, 88, 90
HIV/HCV co-infected patients 87, 87, 88, 89
anti-smooth muscle antibody (ASMA), autoimmune hepatitis diagnosis 144, 146
α-1 antitrypsin deficiency see alpha-1 antitrypsin (AAT) deficiency
antiviral resistance
direct acting antiviral agents 68
nucleoside/nucleotide analogs 48, 49
AP see alkaline phosphatase (AP)
arterial oxygen saturation, in hepatopulmonary syndrome 257, 258, 259
ascariasis 15
ascites 209–226
in children 386
chylous see chylous ascites
classification 209
clinical presentation 213, 214
definition 209
diagnosis 212–216
algorithm 217
clinical 213–215
differential 212–213, 213
imaging techniques 216
laboratory 215, 215–217
potential pitfalls/common errors 217
etiology 210–211
guidelines 226
incidence/prevalence 209
indications for hospitalization 217, 231
infection see spontaneous bacterial peritonitis (SBP)
malnutrition and 345
pathogenesis 211, 212, 386
prevention 211
prognosis 225
refractory see refractory ascites
screening 211, 212
tense 209
in children 386
portopulmonary hypertension vs. 264
treatment 217, 218, 218–223
algorithm 224
bed rest 218, 218
in children 386
diet 218, 218, 345, 349
diuretics 218, 218–221, 219
errors 223–224
large volume paracentesis 218, 221–223
liver transplantation 223
uncomplicated vs. complicated 215
ascitic fluid, macroscopic appearance 214, 213
ascitic fluid analysis
ascites evaluation 216, 216–217, 213
spontaneous bacterial peritonitis diagnosis 230
aspartate aminotransferase (AST) 3, 4, 365
elevated levels 3, 4, 6, 7, 9
in children 366
post-liver transplantation 438
Aspergillus infection, post-liver transplantation 500, 502
aspiration pneumonia 472
asterixis 239, 284
autoimmune cholangitis 153
autoimmune hepatitis (AIH) 142–150
associated conditions 146
classification 142–143
clinical presentation 145
definition 142
diagnosis see autoimmune hepatitis (AIH) diagnosis economic impact 143
etiology 143
follow-up tests and monitoring 149
guidelines 150
histopathology 146, 150
indications for hospitalization 147
overlap syndromes see autoimmune hepatitis–overlap syndromes
Index

pathophysiology 143
post-liver transplantation, de novo see plasma cell hepatitis
post-liver transplantation, recurrent 446, 455, 521, 524, 529
diagnosis 524, 525, 526
incidence/prevalence 522
pathology/pathogenesis 522
screening 523
treatment 526, 527, 528
in pregnancy 149, 273
prevalence 143
prevention 143–144
prognosis 149
risk factors 143
severity classification 146
special populations 149
treatment 147–148, 148, 289
complications, prevention/management 148
effect on prognosis 149
autoimmune hepatitis (AIH) diagnosis 144–147
classification 147
clinical 145–146
differential 145
AAT deficiency vs. 190
alcoholic hepatitis vs. 123
Budd–Chiari syndrome vs. 296
drug-induced liver injury vs. 25, 145
hepatitis A/E vs. 35
hepatitis C vs. 61
HIV/HCV and HIV/HBV co-infections 83
primary biliary cirrhosis vs. 145, 153
imaging techniques 146
laboratory 146, 147
potential pitfalls/common errors 146
simplified diagnostic criteria 144, 146
autoimmune hepatitis–overlap syndromes
classification 143
definition 142
diagnosis 146
treatment 148
autoimmune hepatitis–primary biliary cirrhosis overlap syndrome 143, 146, 153
autoimmune hepatitis–primary sclerosing cholangitis overlap syndrome 143, 146, 149
auxiliary partial orthoptic liver transplantation (APOLT) 398
azathioprine, post-liver transplantation malignancy and 505, 507
bacterial infections
post-liver transplantation 494, 497–499
prophylaxis 496
risk factors 495
treatment 500–502
see also infections, post-liver transplantation
pyogenic liver abscess etiology 104
spontaneous peritonitis see spontaneous bacterial peritonitis (SBP)
balloon tamponade, variceal bleeding treatment 201, 202, 202, 203
band ligation, varices/variceal bleeding 198, 201, 202, 204, 207
in children 386
evidence 207
Banff schema 447, 456
bariatric surgery, non-alcoholic fatty liver disease treatment 138, 138
Baveno V consensus 200
bed rest, ascites treatment 218, 218
benign liver lesions 317
clinical presentation 319
diagnosis 319, 320
algorithms 321, 322
incidence/prevalence 317
see also hepatic cysts; specific types
benign recurrent intrahepatic cholestasis (BRIC) 373
beta-blocker therapy, non-selective see non-selective beta-blocker therapy
bile, tests that evaluate impaired flow in children 366–367
bile acids
abnormal levels 370
metabolism, inborn errors 361
bile duct cysts see Caroli’s disease
bile duct neoplasm see cholangiocarcinoma
biliary atresia
extrahepatic 374, 375, 376, 378
indications for liver transplantation in children 396
biliary complications, post-liver transplantation 437, 439, 475, 486–493
classification 486–487
clinical presentation 489
definition 486
diagnosis 488–489
economic impact 487
etiology 487–488
images 492–493
incidence/prevalence 487
indications for hospitalization 490
live donor transplant 417
prevention 488
prognosis 491
screening 488
treatment 490
algorithm 491
complications, prevention/management 491
biliary infections 111–119
classification 111
clinical presentation 113
definition 111
diagnosis 113–116
clinical 113–114
imaging techniques 115–116
laboratory 115
etiology 112
guidelines 118–119
incidence/prevalence 112
indications for hospitalization 116
pathology/pathogenesis 112
prevention 112–113
prognosis 117–118
severity classification 114–115
treatment 116–117, 117
effect on prognosis 118
biliary leak, post-liver transplantation 432, 487
diagnosis 489
etiology 487–488
image 493
incidence/prevalence 487
treatment 490, 491
algorithm 491
biliary obstruction
causes 7
diagnosis 7–8, 9, 26, 35, 153
biliary stenosis/stricture, post-liver transplantation 432, 440, 487
diagnosis 489
etiology 487
images 492, 493
incidence/prevalence 487
treatment 490, 491
algorithm 491
biliary stones/casts, post-liver transplantation 486, 487, 488
bipedal edema, post liver transplantation 429
bloodstream infections, post-liver transplantation 498, 502
boceprevir therapy, hepatitis C 65, 67
see also protease inhibitors, hepatitis C (HCV PI)
body mass index (BMI) 348
bosentan therapy, portopulmonary hypertension 268, 269
breastfeeding, HBV-infected mothers 50–51
breastfeeding jaundice 376
breast milk jaundice 376
bronchiectasis, alpha-1 antitrypsin deficiency vs. 190
bronchitis, chronic, alpha-1 antitrypsin deficiency vs. 190
Budd–Chiari syndrome 289, 294–300
carcinoid syndrome 294
clinical presentation 296
definition 294
diagnosis 7, 296–297, 303
algorithm 297
clinical 296–297
differential 296, 304
imaging techniques 9, 297
laboratory 297
potential pitfalls/common errors 297
etiology 295
follow-up tests and monitoring 300
incidence/prevalence 294–295
indicators for hospitalization 298
pathology/pathogenesis 295
predictive/risk factors 295, 295
in pregnancy 273, 299
prevention 295–296
prognosis 299–300
screening 296
treatment 298, 298–299
algorithm 299
complications, prevention/management 299
effect on prognosis 300
bile duct obstruction, post liver transplantation 345
bile duct obstruction, post liver transplantation 414
bloodstream infections, post liver transplantation 431, 472
boocprevir therapy, hepatitis C 459
Candida infection, post-liver transplantation 499, 502
carotid artery stenting, post-liver transplantation 489
ceftazidime therapy, spontaneous bacterial peritonitis 231
ceftriaxone therapy, spontaneous bacterial peritonitis 229
cefotaxime therapy, spontaneous bacterial peritonitis 231
chemotherapy, hepatitis B carriers, prophylactic 367
chemoprophylaxis 485
chemotherapy, hepatitis B carriers, prophylactic 485
chemotherapy, hepatitis C carriers, prophylactic 485
chemotherapy, prophylactic 485
chemotherapy, prophylactic 485
childhood liver diseases 159
children
acute liver failure see acute liver failure (ALF), in children
alpha-1 antitrypsin deficiency 190, 194
amebic liver abscess 102
autoimmune hepatitis 149
end-stage liver disease see end-stage liver disease (ESLD), in children
hepatic encephalopathy 353, 354, 363, 387
clinical presentation 355–356, 356, 387
treatment 359, 360, 387
hepatitis A 38
hepatitis B vaccination see hepatitis B vaccination, infants
hepatitis C, treatment 72
jaundice 369
see also neonates, jaundice
liver function tests 365–373
evaluation of excretory function of liver 370–371
evaluation of impaired bile flow/cholestasis 367–368
evaluation of liver injury 365–366, 366
“clinical drug signature” 26, 27
Clostridium difficile colitis, post-liver transplantation 497, 499, 502
clotting factors, liver function tests in childhood 370
CMV infection see cytomegalovirus (CMV) infection
coagulopathy
in acute liver failure 282
treatment 287
in children 387–388
in end-stage liver disease 428
treatment
in acute liver failure 287
in children 388
post-liver transplantation 430
cold ischemia
liver graft 464, 470
see also ischemia–reperfusion injury
colon cancer, post-liver transplantation 505, 507
screening 506
compensated cirrhosis
hepatitis B treatment and 55
hepatitis C treatment and 74
nutritional recommendations 348
screening for varices 198
see also cirrhosis
complementary therapy
hepatic encephalopathy 241
hepatitis C infection 71
complete blood count (CBC)
acute liver failure 285
in children 356–357
alcoholic hepatitis 124
amoxicillin therapy, hepatic abscess 99
Budd–Chiari syndrome 297
in children 371
acute liver failure 356–357
hepatitis C treatment monitoring 68, 69
portal vein thrombosis 303
pyogenic liver abscess 106
computed tomography
alpha-1 antitrypsin deficiency 191–192
amoxicillin therapy, hepatic abscess 100
hepatitis C infection 62
jaundiced patients 18
non-alcoholic fatty liver disease 136
pyogenic liver abscess 106
see also imaging techniques
congenital hepatic fibrosis, in Caroli’s syndrome 310, 315
COPD (chronic obstructive pulmonary disease) 257
see also alpha-1 antitrypsin (AAT) deficiency
copper
hepatic concentration, in Wilson disease 180
metabolism 177
urine, levels in Wilson disease 180
corticosteroid therapy
acute rejection 448, 449, 449, 451
alcoholic hepatitis 127, 128, 128, 129
autoimmune hepatitis 147, 148, 289
Couinaud’s segments 399
critical flicker frequency 239
cryptococcosis, post-liver transplantation 499, 502
culture, ascitic fluid 216
spontaneous bacterial peritonitis diagnosis 230
cyclosporine therapy, liver transplant recipients 433
cystadenoma/cystadenocarcinoma 325
diagnosis 327
imaging 327, 332
incidence/prevalence 326
treatment 328–329, 330
cystic liver lesions see hepatic cysts
cytology, ascitic fluid 216, 217
cytomegalovirus (CMV) infection, post-liver transplantation 439, 497, 514
diagnosis 499
prophylaxis 433, 434, 496
risk factors 495, 499
treatment 502
deceased donor liver transplantation (DDLT), live donor liver transplantation vs. 415
decompensated cirrhosis
clinical presentation 337
hepatitis B treatment and 54–55
hepatitis C treatment and 74
nutritional recommendations 349
post-surgery, predictive/risk factors 335
screening for varices 198
see also cirrhosis
decompression, Budd–Chiari syndrome 298, 299
deferasirox 171, 172
deferoxamine 171, 172
delayed graft function (DGF) 470
dental procedures, antibiotic prophylaxis in liver transplant recipients 535
dexyoxyspergualin 448, 449
depression, hepatitis C treatment side-effect 68, 73
diabetes mellitus, post-liver transplantation 531, 532
management 533
diabetic patients, liver transplantation 413
didanosine, non-cirrhotic portal hypertension and 308, 310
dietary modification
ascites management 218, 218
non-alcoholic fatty liver disease management 138
dilantin-induced liver injury 31
diloxanide furoate therapy, amoxicillin therapy, hepatic abscess 101
children 102
direct acting antiviral agents (DAAs)
in HIV/HCV co-infection 86, 89
resistance 68, 74
see also protease inhibitors, hepatitis C (HCV PI)
diuretic-intractable ascites 216
diuretic-resistant ascites 216
diuretic therapy, ascites in children 386
cirrhotic 218, 218–221, 219
domino liver transplantation 398
Donor Risk Index (DRI) 425
drug-induced liver injury (DiLi) 23–30
clinical presentation 26
definition 23
diagnosis 7, 25–28
algorithm 27
clinical 26–27
differential 25–26, 35, 61, 134
imaging techniques 27
laboratory 27
potential pitfalls/common errors 28
disease classification 23, 27
economic impact 24
etiology 24, 281
guidelines 30
histopathology 27, 31
incidence/prevalence 23
indications for hospitalization 28
latency period 26
liver transplant recipients 439, 440, 455, 514
fibrosis, liver
- congenital, in Caroli’s syndrome 310, 315
- in hepatitis C, staging methods 62
- in HIV-infected patients with HBV/HCV co-infection 78
  - assessment 85, 86
  - predictive/risk factors 80
fluid restriction, ascites treatment 218, 218
- in children 386
focal nodular hyperplasia (FNH) 317, 319
- diagnosis 319, 321, 322
  - prevalence 317
  - see also liver lesions
fructosuria, hereditary 361
fulminant hepatic failure (FHF), pathology/pathogenesis 282
fulminant hepatitis A virus infection 39
fungal infections, post-liver transplantation 497, 499–500
- prophylaxis 434
  - risk factors 495
- treatment 502
  - see also see also infections, post-liver transplantation
furomamide therapy, cirrhotic ascites 218, 219, 220, 221
galactosemia 361
gall stones, in pregnancy 273, 276
- gamma glutamyl transpeptidase (GGT) 4, 5
  - elevated levels 4, 5, 7, 7
  - in children 367
- levels in children 366
- gastric variceal bleeding 197, 200, 201, 208
  - imaging 201, 208
  - surveillance endoscopy 205
  - treatment 201, 202, 204
  - evidence 207
  - see also portal hypertensive bleeding
gastrointestinal bleeding, portal hypertensive see portal
  hypertensive bleeding
gastrointestinal mucosal edema 345
gastropathy, portal hypertensive see portal hypertensive
gastropathy
genotypic resistance, definition 48
- GGT see gamma glutamyl transpeptidase (GGT)
- Gilbert’s syndrome 7, 15
- globulins, serum, liver function tests in childhood 371
  - glucocorticoid therapy see corticosteroid therapy
glycogen storage, impaired, malnutrition and 345
- graft necrosis 463
graft rejection
  - acute see acute rejection
  - chronic see chronic rejection
growth retardation, in children with end-stage liver
  disease 397
  - management 389, 389
guidelines
- acute liver failure 292
- alcoholic hepatitis 130
- alpha-1 antitrypsin deficiency 195
- ascites 226
- autoimmune hepatitis 150
- biliary infections 118–119
- drug-induced liver injury 30
- end-stage liver disease in children 392
- hepatic encephalopathy 244
- hepatitis B 57
- hepatitis C 77
- hepatopulmonary syndrome 261
- hepatorenal syndrome 253
hereditary hemochromatosis 174
HIV/HBV co-infection 95
HIV/HCV co-infection 94, 95
jaundice see under jaundice
- liver lesions 324
- liver test abnormalities 12
- liver transplantation
  - health maintenance after 536
  - infection prophylaxis/management in transplant
    recipients 503
  - patient evaluation 426
  - non-alcoholic fatty liver disease 140
  - nutrition in liver diseases 350
  - portal hypertensive bleeding 206
  - portal vein thrombosis 307
  - primary biliary cirrhosis 158
  - primary sclerosing cholangitis 166
  - spontaneous bacterial peritonitis 234
  - Wilson disease 185–186
hand-grip strength test 347
HCC see hepatocellular carcinoma (HCC)
HELLP (hemolytic anemia, elevated liver enzymes and low
  platelet count) syndrome 11, 289
  - classification systems 274
  - diagnosis 275, 275, 276
  - incidence/prevalence 272
  - pathogenesis 272
  - predictive/risk factors 272
  - presentation 273, 274
  - prognosis 278
  - treatment 276, 277, 277
hemangioma, hepatic see hepatic hemangioma
hemochromatosis
  - hereditary see hereditary hemochromatosis (HH)
- neonatal 362, 363, 364
hemodialysis patients, hepatitis C treatment 72, 74
- hemolytic uremic syndrome 273
- hemophagocytic lymphohistiocytosis 362, 363
- hemophagocytic syndrome 362, 364
- heparin therapy, Budd–Chiari syndrome 298, 299
hepatic abscess
  - amebic see amebic liver abscess
  - pyogenic see pyogenic liver abscess
hematological abnormalities 317
  - clinical presentation 319
  - complications 319
  - diagnosis 319, 321, 322
  - risk factors 318
  - treatment 320
hepatic artery pseudoaneurysms 484–485
- hepatic artery stenosis, post-liver transplantation 432,
  438, 483
diagnosis 446, 455, 514
hepatic artery thrombosis (HAT), post-liver
  transplantation 431, 438, 482–485
diagnosis 440, 446, 455, 483–484, 514
  - incidence/prevalence 482
  - management/therapeutic algorithm 484
  - pathology/pathogenesis 483
  - predictive/risk factors 483
hepatic cysts 317, 325–333
  - classification 325
  - definition 325
  - diagnosis 319, 321, 326–328
  - etiology 326
  - images 331–333
  - incidence/prevalence 317, 325–326
simple see simple hepatic cysts
treatment 328–329, 329–330
see also specific types
hepatic encephalopathy 235–244
in children see children
classification 235–236, 236
clinical presentation 235, 238
definition 235
diagnosis 238–240
clinical 238–239, 239, 284
differential 238
laboratory 239
potential pitfalls/common errors 240
economic impact 236
etiology 236
guideline 244
incidence/prevalence 236
indication for hospitalization 241
minimal see minimal hepatic encephalopathy (MHE)
predictive/risk factors 237
prevention 237–238
prognosis 243
severity classification 237, 285, 285
treatment 240–242, 241, 287
algorithms 240, 242
complications, prevention/management 242
effect on prognosis 243
elderly patients 243
hospitalized patients 240, 241
malnutrition and 345
outpatient setting 242
hepatic hemangioma 317
diagnosis 319, 321, 322
prevalence 317
hepatic hematoma/rupture, in pregnancy 274
prognosis 278
treatment 276, 277, 277
hepatic hydrothorax 428
hepatic lesions see liver lesions
hepatic steatosis
definition 132
donor liver, as primary non-function risk factor 463
pathogenesis 133
hepatic venous occlusion, post-liver transplantation 432, 477–480
clinical presentation 478–479
diagnosis 478–479
algorithm 479
etiology 478
incidence/prevalence 478
management/therapeutic algorithm 480
predictive/risk factors 479
hepatitis
alcoholic see alcoholic hepatitis
autoimmune see autoimmune hepatitis (AIH)
cholestatic see cholestatic hepatitis
plasma cell see plasma cell hepatitis
viral see viral hepatitis
hepatitis A 32–40
clinical presentation 34, 35
definition 32
diagnosis 34–37, 273
clinical 36
differential 35
imaging techniques 37
laboratory 37
potential pitfalls/common errors 37
economic impact 32
etiology 33
extrahepatic manifestations 36
guidelines 40
incidence/prevalence 32
indications for hospitalization 37
pathology/pathogenesis 33
predictive/risk factors 33
prevention 33–34, 34
prognosis 39
relapsing 39
severity classification 36
special populations 38
treatment 37–38, 38
algorithm 38
hepatitis B 41–57
acute 43
definition 78
chronic 41, 43, 83
definition 78
in HIV-infected patients see HIV/HBV co-infection
clinical presentation 43, 83
diagnosis 35, 43–45, 61
clinical 43, 84
in HIV-infected patients 83–84, 85
laboratory 43–45, 45, 84
potential pitfalls/common errors 45
etiology 41, 79
guidelines 57
hepatitis D co-infection 56
HIV co-infection see HIV/HBV co-infection
imaging techniques 45
incidence/prevalence 41
pathology/pathogenesis 42, 79
prevention 42–43
in immunosuppression 55–56, 283
post-liver transplantation 433, 434, 522, 523, 524
screening 524
treatment 526, 527, 528
screening 42
in HIV-infected patients 80, 81
pre-chemotherapy 282, 283
pre-natal 52
special populations 50–56
patients undergoing immunosuppressive therapy/chemotherapy 55–56
pregnant women see pregnant women
treatment 46, 46–50
in compensated/decompensated cirrhosis 54–55
EASL guidelines 45
goals 46
in HIV-infected patients see HIV/HBV co-infection
interferons 46, 48
nucleoside/nucleotide analogs 46, 46–47, 47
in pregnancy 50, 51, 54, 55, 93
prevention/management of complications (viral resistance) 48, 49
hepatitis B vaccination 42–43
economic benefits 79
HIV-infected patients 81
algorithm 82
infants
born to HBsAg-positive women 52, 53
born to HIV-infected women 81
born to women with unknown HBsAg status 53, 53
pregnant women 43, 52
hepatitis C 58–77
acute 61, 78
chronic 61, 78, 83
clinical presentation 61, 83
definition 58
diagnosis 35, 60–64
algorithm 61
differential 61–62
in HIV-infected patients 83–84, 85
laboratory 63, 63, 84
post-liver transplantation see hepatitis C recurrence, post-liver transplantation
potential pitfalls/common errors 64
economic impact 59, 79
HIV co-infection 79
recurrent HCV, post-liver transplantation 513
etiology 59, 79
evidence 77
follow-up tests and monitoring 76
guidelines 77
HIV co-infection see HIV/HCV co-infection
imaging techniques 63, 84
recurrent HCV, post-liver transplantation 515
incidence/prevalence 58–59, 78
indications for hospitalization 70
pathology/pathogenesis 59, 79
predictive/risk factors 59
prevention 59–60, 81, 82
prognosis 75–76, 76
recurrent see hepatitis C recurrence, post-liver transplantation
screening 60
in HIV-infected patients 80
recurrent HCV, post-liver transplantation 514
severity classification 62–63
sustained virological response (SVR) 64, 67, 72
effect of IL28B genotype 70
in HIV-infected patients 86
predictors 75, 88
rates in genotype 1 70, 75, 76
rates in genotypes 2 and 3 75
see also hepatitis C treatment
hepatitis C recurrence, post-liver transplantation 437, 438, 439, 448, 512–520
classification 512
clinical presentation 514, 515
complications, prevention/management 516
definition 512
diagnosis 514–515
algorithm 515
differential 514
economic impact 513
etiology 513
factors associated with accelerated fibrosis progression 513
histopathology 515, 519
HIV co-infected patients 517
incidence/prevalence 512, 521
indications for hospitalization 516
pathology/pathogenesis 513
prevention 513–514
prognosis 517–518
screening 514
treatment 516, 516–517
hepatitis C treatment 64–75, 70–71, 73
abbreviations and definitions 64
adherence 68
algorithms 65, 73, 74
delay, acute HCV 75
effect on prognosis 75, 76
efficacy 67
genotype 1 HCV 65–66, 65, 66, 71
sustained virological response rates and 75, 76
treatment-experienced patients 66, 67
genotypes 2 and 3 HCV 66, 71, 73, 75
genotypes 4, 5 and 6 HCV 66, 71
in HIV-infected patients see HIV/HCV co-infection
IL28B genotyping and 70
monitoring 67–68, 69
recurrent HCV, post-liver transplantation 516, 516–517
side-effects 68
prevention/management 68, 71–72
special populations 72, 74–75, 93
treatment-experienced patients 66
see also protease inhibitors, hepatitis C (HCV PI)
hepatitis D 56
hepatitis E 32–40
clinical presentation 34, 35
diagnosis 34–37, 273
clinical 36
laboratory 37
potential pitfalls/common errors 37
economic impact 32
etiology 33
guidelines 40
indications for hospitalization 37
pathology/pathogenesis 33
prevalence 32
prevention 33–34
prognosis 39
severity classification 36
special populations 38
special populations 38
treatment 37–38, 38
hepatobiliary scintigraphy, jaundiced infants 377–378
hepatocellular carcinoma (HCC) 317
in children 391–392
clinical presentation 319, 391
diagnosis 319, 320
algorithms 321, 322
prevalence 318
recurrent, post-liver transplantation 509
surveillance 506, 506
risk factors 318
screening 44, 62, 93, 318, 323
post-liver transplantation 506, 506
hepatocellular carcinoma (HCC) treatment 323
in children 392
liver transplantation 407
disease surveillance 411, 413
patient evaluation 409, 412, 422
hepatocellular injury, liver test abnormalities 3, 4, 5, 23
evaluation 6–7, 7
algorithm 10
hepatolenticular degeneration see Wilson disease
hepatoporal sclerosis, treatment 422
hepatopulmonary syndrome (HPS) 255–262
  in children 387
  clinical presentation 257
  in children 387
  definition 255, 387
  diagnosis 256–260, 387
    algorithm 259
    clinical 257–258
    differential 257
    imaging techniques 258–259, 259
    laboratory 258
    portopulmonary hypertension vs. 264, 266
  potential pitfalls/common errors 260
  economic impact 255
  etiology 256
  evidence 262
  guidelines 261
    incidence/prevalence 255
    pathology/pathogenesis 256
    prognosis 261
    screening 256
    severity classification 258
    treatment 260, 260
hepatorenal syndrome (HRS) 245–254, 282
  in children 391
  clinical presentation 248, 391
  definition 245
  diagnosis 247–249
    clinical 248–249
    differential 247, 248, 391
    laboratory 249
    potential pitfalls/common errors 249
  epidemiology 245
  etiology 245–246
  guidelines 253
    hospitalization of patients 250
    imaging techniques 249
  pathogenesis 246, 246, 282
  predictive factors 246–247
  prevention 247
  prognosis 252
  screening 247
  severity classification 249
  treatment 249–251, 391
    liver transplantation 251, 252
    pharmacological 250–251
    post-liver transplantation 429–430
    transjugular intrahepatic portosystemic shunting 251
hepatotoxicity
  amiodarone, diagnosis 123
  antiretroviral 83, 83
  see also drug-induced liver injury
  hepcidin 168
  hereditary fructosemia 361
  hereditary hemochromatosis (HH) 167–175
    classification 167
    clinical presentation 170
    definition 167
    diagnosis 169–171
      algorithm 172
      clinical 170
      differential 169
      imaging techniques 171
      laboratory 170
      potential pitfalls/common errors 171
    economic impact 168
    etiology 168
    evidence 174
follow-up tests and monitoring 173
  guidelines 174
  incidence/prevalence 167–168
  pathology/pathogenesis 168
  pregnancy and 173
  prevention 169
  prognosis 173
  screening 169
  treatment 171–172, 171–173
    algorithm 172
  herpes simplex virus infection, acute liver failure
    diagnosis 7
    in neonates 358, 362, 363
  HIV/HBV co-infection 78–95
    clinical presentation 83
    definition 78
    diagnosis 83–86
      algorithm 83
      clinical 84
      differential 84
      laboratory 85
      potential pitfalls/common errors 86
    etiology 79
    follow-up tests and monitoring 93
    guidelines 95
    imaging techniques 85
    liver fibrosis
      assessment 85, 86
      risk factors for progression 80
      pathology/pathogenesis 79
    prevalence 78
    prevention 80–82
    prognosis 93
    screening 80
      algorithm 81
      treatment 86–92, 90–92
    etiology 79
    complications, prevention/management 92
    effect on prognosis 93
  HIV/HCV co-infection 78–95
    clinical presentation 83
    definition 78
    diagnosis 83–86
      algorithm 83
      clinical 84
      differential 84
      laboratory 85
      potential pitfalls/common errors 86
    etiology 79
    follow-up tests and monitoring 93
    guidelines 94, 95
    imaging techniques 85
    incidence/prevalence 78, 79
    indications for hospitalization 90
    liver fibrosis 78
      assessment 85, 86
      risk factors for progression 80
    pathology/pathogenesis 79
    prevention 80–82
    prognosis 93
    recurrent HCV, post-liver transplantation 517
    screening 80
    treatment 86–92, 90–92
    algorithms 87, 88
    complications, prevention/management 92
    effect on prognosis 93
    evaluation 89–90
HIV/HCV co-infection  (cont’d)  
HIV/HCV genotype 1 patients 87–89, 88, 87  
HIV/HCV genotype 2 and 3 patients 89, 88  
HIV/HCV genotype 4 patients 91, 87  
HIV-infected patients  
HBV co-infection see HIV/ HBV co-infection  
HCV co-infection see HIV/HCV co-infection  
Liver transplantation 413, 425  
HOMA (homeostasis model assessment) 135  
HRS see hepatorenal syndrome (HRS)  
yellowed cysts   325  
diagnosis 98, 105, 327–328  
etiology 326  
ingaging 328, 333  
 incidence/prevalence   326  
treatment 329, 330  
hyperacute rejection 438  
hyperbilirubinemia  5, 13  
conjugated  
causes  14–15  
ingaging  7, 17  
in infancy 370  
see also neonatal cholestasis  
presentation  16  
diagnostic approach 7  
mixed 14  
n neonatal 369–370  
differential diagnosis 375–376, 376  
see also neonatal cholestasis  
unconjugated 7, 14, 15, 18, 369  
see also jaundice  
hypercholesterolemia, primary biliary cirrhosis  
association 156  
hypermucosis gravidarum 10  
diagnosis 273, 274, 275, 276  
 incidence/prevalence   272  
predictive/risk factors 272  
presentation 273, 276  
progression 278  
treatment 276, 277  
hyponatremia, liver donor, as primary non-function risk factor 463  
hypertension  
intracranial, in acute liver failure 281  
portal see portal hypertension  
portopulmonary see portopulmonary hypertension (PPHTN)  
post-liver transplantation 531, 532, 532  
management 533  
hypertension-related liver diseases in pregnancy 271  
presentation 274  
progression 278  
see also HELLP (hemolytic anemia, elevated liver enzymes and low platelet count) syndrome; pre-eclampsia  
hypoglycemia, in acute liver failure 282, 285  
hypomagnesemia, post-liver transplantation 430  
hyponatremia, post-liver transplantation 430  
Hy’s law 27, 29, 30  
ICH (intracranial hypertension), in acute liver failure 281  
ideal body weight (IBW) 348  
idiotropic adulthood ductopenia 153  
idiotropic portal hypertension see obliterator portal venopathy (OPV)  
IgG4 sclerosing cholangitis, primary sclerosing cholangitis vs. 162, 164  
IL28B genotyping 70  
iloprost therapy, portopulmonary hypertension 268  
imaging techniques  
acute liver failure see acute liver failure (ALF)  
alcoholic hepatitis 125  
alpha-1 antitrypsin deficiency 191–192  
amoebic liver abscess 100, 328  
asces 216, 217  
autoimmune hepatitis 146  
biliary infections 115–116  
Budd–Chiari syndrome 9, 297  
Carol’s disease 327, 332  
cystadenoma 327, 332  
drug-induced liver injury 27  
hepatitis A 37  
hepatitis C see hepatitis C, imaging techniques  
hepatitis E 37  
hepatocellular carcinoma screening 44, 62  
hapatopulmonary syndrome 258–259, 259  
hepatorenal syndrome 249  
hereditary hemochromatosis 171  
yellowed cysts 328, 333  
investigation of liver test abnormalities 9  
jaundiced patients see under jaundice  
liver transplantation assessment  
in children 397  
donor evaluation, live donor liver transplantation 417  
liver transplant recipients 431  
acute rejection 447  
biliary complications 489  
chronic rejection 457  
ischemia–reperfusion injury 473  
post-transplant lymphoproliferative disorder 509  
primary non-function 465, 466  
recurrent disease 515, 525–526  
venous complications 479, 481, 484  
non-alcoholic fatty liver disease 9, 136  
nocircbosis portal hypertension 312  
patients with liver disease presenting for surgery 338  
polyclastic liver disease 327, 332  
potral hypertension bleeding 201  
portal vein thrombosis 304  
portopulmonary hypertension 266  
pregnancy-related liver disease 275  
primary biliary cirrhosis 154  
primary sclerosing cholangitis 8, 9, 163  
pyogenic liver abscess 106, 328  
simple hepatic cysts 326–327, 331  
spontaneous bacterial peritonitis 231  
Wilson disease 181  
imunization see vaccinations  
imunoglobulin, hepatitis A prevention 34, 34  
imunosuppressive therapy  
autoimmune hepatitis 147, 148  
hepatitis B carriers, prophylactic measures 55–56, 283  
liver transplant recipients 433, 433, 445–446  
acute rejection treatment see acute rejection, treatment  
chronic rejection treatment see chronic rejection, treatment  
ischemia–reperfusion injury prevention 472  
pediatric, adherence 400–401  
in post-liver transplantation malignancy 505  
prevention of acute rejection 445–446  
prevention of chronic rejection 454–455  
see also specific immunosuppressive agents  
incoplete septal cirrhosis (ISC) 311  

infants see children; neonates
infections
  in acute liver failure 282
    treatment 287
  biliary see biliary infections
  see also specific infections
infections, post-liver transplantation 433, 437, 446, 494–503
  classification 494
  clinical presentation 496, 497
  diagnosis 496–500
    0–30 days 496–497, 500
    31–180 days and beyond 497, 501
  algorithms 500, 501
  bacterial infections 497–499
  fungal infections 499–500
  viral infections 499
  incidence/prevalence 494
  indications for hospitalization 502
  pathology/pathogenesis 494–495
  predictive/risk factors 495
  prophylaxis 433–434, 495–496
    screening 495
  treatment 500–502
inflammation, ischemia–reperfusion injury
  pathogenesis 470–471
  informed consent, liver transplantation 424
  insulin resistance
    in cirrhosis 345
    homeostasis model assessment 135
  interface hepatitis, in autoimmune hepatitis 146, 150
  interferon therapy
    hepatitis B infection 46, 48
    see also pegylated interferon (PEG-IFN) therapy
  International Ascites Club, hepatorenal syndrome diagnostic criteria 249
  international normalized ratio (INR) 369
  intracranial hypertension (ICH), in acute liver failure 281
  intrahepatic cholestasis of pregnancy (ICP) 10
    diagnosis 273, 274, 275, 275
    etiology 272
    incidence/prevalence 272
    predictive/risk factors 272
    presentation 273, 276
    prognosis 278
    treatment 276, 277
  intrapartum infection, hepatitis B 51
  intrapulmonary vascular dilatations (IPVDs) 255, 256, 258
  intrauterine transmission, hepatitis B 51
  iron chelation therapy, hereditary hemochromatosis 171, 172
  iron homeostasis 168
  iron studies, hereditary hemochromatosis 169, 170
  ischemia–reperfusion injury 463, 469–476
    in children 475
    clinical presentation 473
    complications, prevention/management 475
    definition 469
    diagnosis 473
      algorithm 474
      differential 472
    etiology 470
    pathology/pathogenesis 470–471
    predictive/risk factors 471
    prevention 471–472, 474
    treatment 474–475
  isoniazid-induced liver injury 31
jaundice 13–22, 369
  in children 369
    see also neonates, jaundice
  classification 13–14
  clinical presentation 16
  definition 13
  etiology 14–15
  evidence 21
  guidelines 21
    in infants 381
  imaging techniques 17–18, 22
    in infants 377–378
  incidence/prevalence 14
  indications for hospitalization 18
  investigations 16–18
    algorithm 20
    clinical 16
    laboratory 17
    potential pitfalls/common errors 18
    in neonates see neonates, jaundice
  physiologic 376
  prognosis 21
  special populations 19–20
  treatment 18–19, 19
    complications, prevention/management 19
    see also hyperbilirubinemia
Kayser–Fleischer rings 177, 179, 180, 181, 186
kernicterus 369
King's College Criteria 27, 290, 290
Kristalose 240
Kupffer cells
  ischemia–reperfusion injury pathogenesis 470–471
  malfunction in acute liver failure 282
lacate, liver function evaluation 371
lactate dehydrogenase (LDH), ascitic fluid 216
lactulose, hepatic encephalopathy treatment 240, 241, 242, 243
  complications 242
  hospitalized patients 240, 241
lamivudine therapy, hepatitis B infection 46, 48
  resistance 49
  large volume paracentesis (LVP) 218, 221–223
  lesions, liver see liver lesions
leukocytosis, in acute liver failure 285
Lille score 124, 129
lipodystrophy 135
live donor liver transplantation (LDLT) 415–420
  advantages 399, 415
  basic principles 415–416
  in children 399, 425
  disadvantages 399
  donor benefits 416
  donor evaluation 416, 417, 418
  donor outcomes 418, 419
  donor selection criteria 416
  patient evaluation 416
  post-operative complications 417, 419
  types of donation 416–417
liver abscess 96–109
  amebic see amebic liver abscess
  pyogenic see pyogenic liver abscess
  liver biopsy
    alcoholic hepatitis 124
    autoimmune hepatitis 146, 147
Index

liver biopsy  (cont’d)
drug-induced liver injury  7, 27
hepatitis C infection  62
jaundiced patients  17
infants  377
liver fibrosis assessment in HIV-infected patients  85
liver transplant recipients  437, 438, 439
percutaneous complications  19
jaundiced patients  17
portal vein thrombosis  304
primary biliary cirrhosis  154
primary sclerosing cholangitis  163
see also liver histopathology
liver fibrosis see fibrosis, liver
liver flukes  15
liver function tests
in childhood see under children
see also liver test abnormalities
liver histopathology
acute rejection  446, 452
alcoholic hepatitis  124–125, 131
alpha-1 antitrypsin deficiency  191, 191
autoimmune hepatitis  146, 150
chronic rejection  455, 461
drug-induced liver injury  27, 31
fibrosing cholestatic hepatitis  519
non-cirrhotic portal hypertension  311, 316
plasma cell hepatitis  520
recurrent hepatitis C, post-liver transplantation  515, 519
Wilson disease  180
see also liver biopsy
liver injury
drug-induced see drug-induced liver injury
liver enzyme patterns  5
liver enzyme tests  3–4, 4–5
in children  365–366
see also liver test abnormalities
liver lesions  317–324
classification  317
clinical presentation  319
cystic see hepatic cysts
diagnosis  318–320
algorithms  321, 322
clinical  319–320
imaging techniques  320
laboratory  320
potential pitfalls/common errors  320
economic impact  318
follow-up tests and monitoring  323
guidelines  324
incidence/prevalence  317–318
infectious  317
see also amebic liver abscess; hydatid cysts; pyogenic liver abscess
predictive/risk factors  318
prevention  318
screening  318
treatment  320, 323
see also specific types
liver resection, liver transplantation vs.  422
liver re-transplantation
chronic rejection management  458
primary non-function management  462, 466, 467
recurrent hepatitis C management  513, 517–518
liver segments  398–399
liver test abnormalities  3–12
in acute liver failure  285
in alpha-1 antitrypsin deficiency  191
in autoimmune hepatitis  146
classification  5
definition  3–4, 4–5
in drug-induced liver injury  23
evaluation  6–9
algorithms  10, 11
cholestatic liver test elevation  7–8, 11
clinical  8
common errors  9
hepatocellular/mixed liver enzyme elevation  6–7, 7, 10
imaging techniques  9
laboratory  8–9
guidelines  12
in hepatitis A/E infection  37
indications for hospitalization  9
in jaundiced infants  377
in non-alcoholic fatty liver disease  136
in patients presenting for surgery  338
in portal vein thrombosis  304
post-liver transplantation see under liver transplantation (LT)
in pregnancy  10–11
in primary biliary cirrhosis  154
in primary sclerosing cholangitis  163
in Wilson disease  180
see also children, liver function tests
liver transplantation (LT)
for acute liver failure  407, 410
in children  360
decision to proceed with  289–290
effect on prognosis  292
for alcoholic hepatitis  127
for alpha-1 antitrypsin deficiency  188, 193, 193, 194
for Budd–Chiari syndrome  298, 298, 299, 299
in children see liver transplantation (LT), in children
for cirrhotic ascites  233
combined transplant  398, 413
complications see liver transplantation (LT), post-operative complications
contraindications  410, 423
disease recurrence following see recurrent disease, post-liver transplantation
for drug-induced liver injury  28
economic impact
biliary complications  487
pediatric LT  395
in elderly patients see under elderly
graft function following delayed  470
dysfunction see liver transplantation (LT), post-operative complications
normal  469–470
graft types  398, 412
guidelines see under guidelines
health maintenance after  530–537
follow-up tests and monitoring  534–535
guidelines  536
for hepatocellular carcinoma see hepatocellular carcinoma (HCC) treatment
for hepatopulmonary syndrome  260, 260, 261
for hepatorenal syndrome  251, 252
high-risk patients  423
in HIV-infected patients  413, 425
imaging techniques associated with see under imaging techniques
informed consent 424
live donor see live donor liver transplantation (LDLT)
liver test abnormalities following 430, 431, 436–443
in acute rejection 447
in chronic rejection 457
early post-transplant period (first 6 months) 438,
441
etiology 437
investigation/differential diagnosis 436, 439–440,
439–440, 441, 442
in ischemia–reperfusion injury 473
late post-transplant period (beyond 6 months) 438–
439, 442
presentation 440
prevention 439
in primary non-function 465, 466
prognosis 441
in recurrent disease 525
in recurrent hepatitis C 515
treatment 440
malignancy after see malignancy, post-liver
transplantation
organ allocation system 411–412
patient evaluation see liver transplantation (LT), patient
evaluation
piggyback technique 399
vascular complications 477, 478
for portal vein thrombosis 305, 306, 306
for portopulmonary hypertension 266, 268
post-operative care 427–435
assessment of complications 431
assessment of graft function 430–431
cardiovascular system 429
coagulopathy management 430
electrolytes 430
gastrointestinal system 430
immunosuppression see immunosuppressive therapy
initial evaluation and general
considerations 428–430
pathology/pathogenesis 428
prophylaxis 433–434, 434
renal system 429–430
respiratory system 429
post-operative complications see liver transplantation
(LT), post-operative complications
in pregnancy 412, 425
for pregnancy-related liver disease 276, 277, 277,
278
for primary biliary cirrhosis 156
for primary sclerosing cholangitis 164, 164
prognosis 413, 427
recurrent liver disease following 528
re-transplantation see liver re-transplantation
types 398
vaccinations after 534–535
vaccinations prior to 496
for Wilson disease 182, 183
liver transplantation (LT), in children 394–403, 425
for acute liver failure 360
approach, algorithm for 401
complications, ischemia–reperfusion injury 475
contraindications 395
economic impact 395
evaluation for 396
laboratory tests and imaging 397
history 394
immunosuppressive therapy adherence
following 400–401
incidence/prevalence 395
indications 395
interim care 397
listing for 398
live donor liver transplantation 399, 425
liver segments 398–399
Pediatric End-stage Liver Disease (PELD) scoring
system 388, 398
post-transplant lymphoproliferative disorder
following 399–400
technical aspects 399
timing of 395–396
transition to adult services 401
types 398
liver transplantation (LT), patient evaluation
407–414
common etiologies 407–408, 408
follow-up tests and monitoring 413
indications for 409, 409–410
live donor liver transplantation 416
MELD score see MELD (Model for End-stage Liver
Disease) score
Milan criteria 408–409
multidisciplinary approach 410–411
surgical 421–426
algorithm 423
informed consent 424
necessity 422
potential pitfalls/common errors 422
strategy 424
suitability 423
typical presentations 422
tests 411
University of California San Francisco (UCSF)
criteria 409
liver transplantation (LT), post-operative complications
biliary see biliary complications, post-liver
transplantation
bleeding 431, 472
general medical conditions 530–537
associated risk factors 530, 531
diagnosis 531
incidence/prevalence 530
prevention 531
prognosis 534
graft dysfunction 431
causes 431, 431–433
see also specific causes
time course 436–437
infections see infections, post-liver transplantation
ischemia–reperfusion injury see ischemia–reperfusion
injury
malignancy see malignancy, post-liver transplantation
physical examination see physical examination, liver
transplant recipients
primary non-function see primary non-function (PNF)
rejection
acute see acute rejection
chronic see chronic rejection
screening see screening, liver transplant recipients
vascular see vascular complications, post-liver
transplantation
living donor liver transplantation see live donor liver
transplantation (LDLT)
loop diuretics, cirrhotic ascites treatment 218, 219,
220
lymphohistiocytosis, hemophagocytic 362, 363
Index

macronutrient deficiency 344
findings 348
see also malnutrition
Maddrey Discriminant Function 126, 127, 129
magnetic resonance cholangiopancreatoigraphy (MRCP), jaundiced patients 18, 22
infants 378
magnetic resonance imaging (MRI)
hepatitis C 62
non-alcoholic fatty liver disease 136
pyogenic liver abscess 106
see also imaging techniques
malignancy, post-liver transplantation 504–511
de novo 504, 505, 507–508
incidence 504, 505, 507
risk factors 507–508
screening 506, 506

treatment 508
diagnosis 507
etiology 505
incidence/prevalence 504–505, 505
pathology/pathogenesis 505
post-transplant lymphoproliferative disorder see post-transplant lymphoproliferative disorder (PTLD)
predictive/risk factors 505
prevention 506–507
recurrent hepatocellular carcinoma see under hepatocellular carcinoma (HCC)
screening 506, 506
treatment 507
see also specific cancers
malignant infiltration, acute liver failure and 289
malignant liver neoplasms
primary 317
see also cholangiocarcinoma; hepatocellular carcinoma (HCC)
secondary see metastatic liver disease
Mallory–Denk bodies 131
malnutrition 344–350
in children with chronic liver disease 388
assessment and management 388–391, 389
classification 344
clinical presentation 346, 347, 347–348
definition 344
diagnosis 346–348
clinical 347–348, 347–348
laboratory 348
potential pitfalls/common errors 348
economic impact 345
etiology 345, 388
follow-up tests and monitoring 349–350
guidelines 350
incidence/prevalence 344–345
pathology/pathogenesis 345
predictive/risk factors 345
prevention 346
prognosis 349
screening 346
treatment 348–349
evidence 350
marginal liver grafts 413, 466
Mayo Natural History Model, primary biliary cirrhosis 154, 162
medium chain acyl-CoA dehydrogenase (MCAD) deficiency 361
MELD (Model for End-stage Liver Disease) score alcoholic hepatitis 126, 127, 128
hepatorenal syndrome 252
patient evaluation for liver transplantation 408, 422
frequency of re-certification 411, 411, 412
live donor liver transplantation 416
pre-operative assessment of patients with liver disease 334, 338, 339, 340
primary biliary cirrhosis 154
metabolic derangements, in acute liver failure 282, 283
treatment 288
metabolic liver diseases
acute liver failure etiologies 281
diagnosis 26, 35
liver transplant indications 410
in children 395
see also specific diseases
metabolic syndrome
definition 135
post-liver transplantation 530, 532, 533
metastatic liver disease 317
diagnosis 319
algorithms 321, 322
prevalence 318
methylprednisolone therapy, liver transplant recipients 433
acute rejection treatment 449
metronidazole therapy
amebic liver abscess 100, 103, 329, 330
in children 102
hydatid cysts 329, 330
micronutrient deficiency 344
see also malnutrition
midodrine therapy, hepatorenal syndrome 250
Milan criteria 408–409
milk thistle 71
mineral deficiency, findings 347
minimal hepatic encephalopathy (MHE) 236, 243
diagnosis 239
Mississippi system, HELP syndrome classification 274
mitochondrial respiratory chain disease 361
MMF see mycophenolate mofetil (MMF) therapy
Model for End-stage Liver Disease see MELD (Model for End-stage Liver Disease) score
mother-to-child transmission (MTCT), hepatitis B 41, 50–51
prevention/management 52–53, 53, 54
algorithms 52, 55
risk assessment algorithm 52
risk factors/likelihood 51
MRCP see magnetic resonance cholangiopancreatoigraphy (MRCP)
MRI see magnetic resonance imaging (MRI)
multidisciplinary approach, evaluation of patients for liver transplantation 410–411
Murphy's sign 114
mushroom poisoning 282, 288
mycophenolate mofetil (MMF) therapy, liver transplant recipients 433
acute rejection treatment 449
chronic rejection treatment 458
complications, prevention/management 458
myocardial infarction (MI), post-liver transplantation 472
NAC (N-acetylcysteine) therapy
acetaminophen toxicity 28, 288
ischemia–reperfusion injury 472, 474
NAFLD see non-alcoholic fatty liver disease (NAFLD)
NCPH see non-cirrhotic portal hypertension (NCPH)
necrosis, graft 463
neonatal cholestasis 370, 374–381
clinical presentation 377
definition 374
diagnosis 375–378
algorithm 376
clinical 377
laboratory 366–367, 378
potential pitfalls/common errors 379
etiology 374
guidelines 381
imaging techniques 378–379
incidence/prevalence 374
indications for hospitalization 379
pathology/pathogenesis 375
prognosis 380
screening 375
treatment 379, 380
neonatal hemochromatosis 362, 363, 364
neonatal hyperbilirubinemia 369–370
neonatal jaundice 369
neonates
acute liver failure 362–363
jaundice 369
differential diagnosis 375–377, 377
incidence/prevalence 374
see also neonatal cholestasis
neuropsychological tests, hepatic encephalopathy 239
neutropenia, hepatitis C treatment side-effect 68, 73
neutrophils, malfunction in acute liver failure 282
nitric oxide, role in hepatopulmonary syndrome
pathogenesis 256
nitrogenous substances, in hepatic encephalopathy
pathogenesis 236
nitroimidazole derivatives, amebic liver abscess
treatment 100
nodular regenerative hyperplasia (NRH) 308, 309, 310, 312, 314
associated diseases 311–312
liver biopsy findings 311, 316
management 313, 313
non-alcoholic fatty liver disease (NAFLD) 132–141
classification 132
clinical presentation 134
complications, prevention/management 138
definition 132
diagnosis 134–137
algorithm 138
clinical 135–136
differential 134
imaging techniques 9, 136
laboratory 136
potential pitfalls/common errors 136–137
economic impact 133
etiology 133
evidence 140
guidelines 140
incidence/prevalence 132
pathology/pathogenesis 133
predictive/risk factors 133, 133
prevention 133–134
prognosis 139
screening 134
treatment 137, 137–138
algorithm 138
non-alcoholic steatohepatitis (NASH) 132
de novo, liver transplant recipients 438
diagnosis 6–7, 7
alcoholic liver disease vs. 123
clinical 135
hepatitis C vs. 61
imaging techniques 9, 136
laboratory 136
monitoring 139
pathogenesis 133
prevalence 132
prognosis 139
recurrence, post-liver transplantation 438, 521, 524
diagnosis 525, 526
etiology 522
incidence/prevalence 522
prevention 523
prognosis 529
treatment 527, 528
severity classification 135–136
treatment 138, 138
see also non-alcoholic fatty liver disease (NAFLD)
non-cirrhotic portal hypertension (NCPH) 199, 308–316
classification 308
clinical presentation 310
definition 308
diagnosis 310–312
algorithm 312
clinical 310–311
differential 310
imaging techniques 312
laboratory 311
liver biopsy findings 311, 316
potential pitfalls/common errors 312
etiology 309
images 315–316
incidence/prevalence 308
indications for hospitalization 313
pathology/pathogenesis 309
predictive/risk factors 309
prevention 309–310
prognosis 314
screening 309
special populations 314
treatment 313, 313
algorithm 313
non-selective beta-blocker therapy, portal hypertensive bleeding 198, 205
in children 385
norfloxacin, spontaneous bacterial peritonitis prophylaxis 229
nuclear scanning, hepatopulmonary syndrome
diagnosis 259, 259
nucleoside/nucleotide analogs
hepatitis B prophylaxis, pre-chemotherapy/
immunosuppressive therapy 283
hepatitis B treatment 46, 46–47, 47
viral resistance 48, 49
number connection test 239, 239
nutritional assessment 346, 347
children with chronic liver disease 388, 390
algorithm 389
nutritional problems see malnutrition
nutritional support, children with chronic liver disease 389, 390
management 313, 313
obliterative portal venopathy (OPV) 308, 309, 310, 312, 314
liver biopsy findings 311, 316
management 313, 313
Index

obstructive cholangiopathy, post-liver transplantation 446, 455
octreotide therapy
hepatorenal syndrome 250
portal hypertensive bleeding 201, 202, 203
in children 386
evidence 207
OKT3 448, 449
organ transplant recipients
hepatitis E infection 35
see also liver transplantation (LT)
orthopedic surgery, in patients with liver disease, mortality rates 337, 340
orthotopic liver transplantation 398
see also liver transplantation (LT)
osteoporosis
post-liver transplantation 533–534
primary biliary cirrhosis association 156
oxygen saturation, in hepatopulmonary syndrome 257, 258, 259
oxygen therapy, hepatopulmonary syndrome 260, 260
paracentesis
diagnostic
ascites evaluation 216, 216–217
spontaneous bacterial peritonitis 215, 230, 231, 232
large volume 218, 221–223
parasitic liver cysts 325
amebic liver abscess see amebic liver abscess (ALA)
hydatid cysts see hydatid cysts
parenteral nutrition 349
paromomycin therapy, amebic liver abscess 101
children 102
Pediatric End-stage Liver Disease (PELD) scoring system 388, 398
pediatrics see children
pegylated interferon (PEG-IFN) therapy
hepatitis B 46, 48
hepatitis C 64, 71, 73
adherence 68
genotype 1 HCV 64–65, 66, 71
genotypes 2 and 3 HCV 65, 71, 74
genotypes 4, 5 and 6 HCV 65
in HIV-infected patients 86, 87, 89, 90, 91
recurrent, post-liver transplantation 516, 517
response, IL28B genotype and 70
treatment-experienced patients 66
see also hepatitis C treatment
D-penicillamine, Wilson disease treatment 182, 183
complications, prevention/management 183
pentoxifylline therapy, alcoholic hepatitis 127, 128, 128, 247
percutaneous transhepatic cholangiography (PTC) 116, 117
peritoneal carcinomatosis 229
peritoneal tuberculosis 229
peritoneovenous shunt (PVS), refractory ascites treatment 222
peritonitis, bacterial
post-liver transplantation 498, 502
secondary 229
spontaneous see spontaneous bacterial peritonitis (SBP)
phenoxypropane, alpha-1 antitrypsin deficiency 191
phlebotomy, hereditary hemochromatosis treatment 171, 171, 173
complications, prevention 172
physical examination
acute liver failure 283, 284
in children 356, 356
alcoholic hepatitis 124
alpha-1 antitrypsin deficiency 190
amebic liver abscess 99
ascites 214
autoimmune hepatitis 145
biliary infections 114
Budd–Chiari syndrome 297
drug-induced liver injury 26
hepatic encephalopathy 238–239
hepatitis A 36
hepatitis C 61–62
hepatopulmonary syndrome 257
hepatorenal syndrome 248
hereditary hemochromatosis 170
investigation of liver test abnormalities 8
jaundiced patients 16
infants 376
liver lesions 320
liver transplant recipients
acute rejection 447
biliary complications 489
chronic rejection 456
ischemia–reperfusion injury 473
primary non-function 465
recurrent disease 515, 525
malnutrition 347
non-alcoholic fatty liver disease 135
non-cirrhotic portal hypertension 311
portal hypertensive bleeding 200
portal vein thrombosis 303
portopulmonary hypertension 265
post-liver transplantation 429
pregnancy-related liver disease 274
pre-operative assessment of liver disease 337
primary biliary cirrhosis 154
primary sclerosing cholangitis 162
pyogenic liver abscess 106
spontaneous bacterial peritonitis 230
Wilson disease 179
physiologic jaundice 376
plasma cell hepatitis 439, 515, 522, 524, 525
in children 528
histopathology 520
treatment 526, 527
pleural effusion, portopulmonary hypertension vs. 264
Pneumocystis jiroveci (carinii) prophylaxis, post-liver transplantation 433, 434, 496
pneumonia, post-liver transplantation 498, 502
PNPLA3 gene variant 133, 133
polycystic kidney disease (PKD), polycystic liver disease association 326, 326
polycystic liver disease (PCLD) 325
diagnosis 327
etiology 326
imaging 327, 332
prevalence 325
treatment 329, 330
polymorphonuclear leukocytes (PMN), ascitic fluid 217, 230
portal hypertension
ascites pathogenesis 211, 212
definition 384
gastrointestinal bleeding and see portal hypertensive bleeding
idiopathic see obliterative portal venopathy (OPV)
non-cirrhotic see non-cirrhotic portal hypertension
pathology/pathogenesis 197, 309
pulmonary hypertension and see portopulmonary hypertension (PPHTN)
portal hypertensive bleeding 196–208
in children 384–386
classification 196
clinical presentation 200
in children 384–385
diagnosis 199–201
in children 385
clinical 200
differential 199
imaging techniques 201
laboratory 200
potential pitfalls/common errors 201
economic impact 196–197
etiology 197
follow-up tests and monitoring 205
guidelines 206
hospitalization of patients 201
images 207–208
incidence/prevalence 196
pathology/pathogenesis 197
predictive/risk factors for esophageal variceal bleeding 197, 197
prevention 197–199
prognosis 205
in children 385
screening 198
severity classification 200
treatment 201–205, 204
algorithm 202–203
in children 385–386
complications, prevention/management 204
effect on prognosis 205
evidence 207
in pregnancy 205
portal hypertensive gastropathy 197, 200
in children 385
portal vein thrombosis (PVT) 301–307
in children 306
classification 301
clinical presentation 303
definition 301
diagnosis 302–304
algorithm 304
clinical 303
differential 303
imaging techniques 304
laboratory 303–304
potential pitfalls/common errors 304
etiology 301–302
guidelines 307
incidence/prevalence 301
indications for hospitalization 305
pathology/pathogenesis 302
post-liver transplantation 432, 480–482
diagnosis 481
incidence/prevalence 480
management algorithm 482
pathology/pathogenesis 480
predictive/risk factors 481
in pregnancy 306
prevention 302
prognosis 306
risk factors 302
screening 302
treatment 305, 305
algorithm 306
complications, prevention/management 305
liver transplantation 425
special populations 306
portopulmonary hypertension (PPHTN) 263–270, 387, 428
classification 263
clinical presentation 265
definition 263
diagnosis 257, 264–266
algorithm 267
clinical 265
differential 264, 266
imaging techniques 266
laboratory 265–266
potential pitfalls/common errors 266
etiology 263
evidence 270
follow-up tests and monitoring 269
incidence/prevalence 263
pathology/pathogenesis 263–264
prognosis 269
pulmonary histology 264
screening 264
severity classification 265
treatment 266–268, 268, 387
algorithm 267
effect on prognosis 269
post-operative care, following liver transplantation see under liver transplantation (LT)
post-transplant lymphoproliferative disorder (PTLD) 508–509
in children 399–400
diagnosis 400, 508
incidence 399, 508
risk factors 399, 508
signs/symptoms 508, 508
treatment 400, 509
potassium-sparing diuretics, cirrhotic ascites
treatment 218, 219, 219–220
prednisone therapy, liver transplant recipients 433
pre-eclampsia 10
diagnosis 273, 274, 275, 276
etiology 272
incidence/prevalence 272
pathogenesis 272
predictive/risk factors 272
presentation 273, 274
prognosis 278
treatment 276, 277
pregnancy
post-liver transplantation 425, 528, 534
recommendations for HBV-infected women who desire pregnancy 54
pregnancy-related liver disease 10–11, 271–279
classification 271–272
clinical presentation 273–274
definition 271
diagnosis 273–276
algorithm 275
clinical 274–275
pregnancy-related liver disease (cont’d)
differential 273
imaging techniques 275
laboratory 275, 275
potential pitfalls/common errors 276
etiology 272
incidence/prevalence 272
indications for hospitalization 276
pathology/pathogenesis 272
predictive/risk factors 272
prevention 272
prognosis 278
severity classification 274–275
treatment 276–278, 277
algorithm 277
pregnant women
abnormal liver tests 10–11, 273, 274, 275
see also pregnancy-related liver disease
acute liver failure 291
alcoholic hepatitis 129
alpha-1 antitrypsin deficiency 194
amebic liver abscess 102
autoimmune hepatitis 149, 273
Budd–Chiari syndrome 273, 299
gall stones 273, 276
hepatitis A 38
hepatitis B 43, 50–54
pre-natal testing 52
treatment 50, 51, 54, 55, 93
vaccination against 52
see also mother-to-child transmission (MTCT)
B
hepatitis C treatment 72, 93
hepatitis E 38
hereditary hemochromatosis 173
jaundice 19–20
liver transplantation 412, 425
non-cirrhotic portal hypertension 314
portal hypertensive bleeding, treatment 205
portal vein thrombosis 306
primary biliary cirrhosis 157
pyogenic liver abscess 108
Wilson disease treatment 184
pre-operative assessment see surgery, in patients with liver
disease
pre-renal kidney failure 247, 248
primary biliary cirrhosis (PBC) 151–159
associated diseases 153
autoimmune hepatitis–PBC overlap syndrome 143, 146, 153
clinical presentation 153
complications, management/prevention 156
definition 151
diagnosis 152–155
algorithm 155
clinical 153–154
differential 153, 273
imaging techniques 154
laboratory 154
potential pitfalls/common errors 155
etiology 152
guidelines 158
incidence/prevalence 151
indications for hospitalization 155
pathology/pathogenesis 152
in pregnancy 157
prevention 152
prognosis 157
risk factors 152
severity classification 154
treatment 155–157, 156
algorithm 156
effect on prognosis 157
primary biliary cirrhosis (PBC) recurrence, post-liver
transplantation 521, 528
diagnosis 524, 525, 526
incidence/prevalence 521, 524
pathology/pathogenesis 522
risk factors 523
treatment 526, 527, 528
primary non-function (PNF) 431, 438, 439, 462–468, 470
clinical presentation 465
definition 462
diagnosis 462, 465, 472
algorithm 466
etiology 462
imaging techniques 465, 466
incidence/prevalence 462, 470
management 465–466
algorithm 467
pathology/pathogenesis 463, 462
predictive/risk factors 463–464, 464
prevention 464, 466, 467
prognosis 467
primary sclerosing cholangitis (PSC) 160–166
autoimmune hepatitis–PSC overlap syndrome 143, 146, 149
classification 160
clinical presentation 162
complications, prevention/management 164
definition 160
diagnosis 161–163
algorithm 163
clinical 162
differential 162
imaging techniques 8, 9, 163
laboratory 163
potential pitfalls/common errors 163
guidelines 166
incidence/prevalence 160
pathology/pathogenesis 161
predictive/risk factors 161
prevention 161
prognosis 165
screening 161
severity classification 162
treatment 164, 164–165
algorithm 165
primary sclerosing cholangitis (PSC) recurrence, post-liver
transplantation 521
diagnosis 523, 524, 525
incidence/prevalence 521, 524
prognosis 528–529
risk factors 523
treatment 526, 527, 528
progressive familial intrahepatic cholestasis
(PHC) 372–373
prostaglandin analogues, primary non-function
management 466, 467
prostaglandin E1, ischemia–reperfusion injury
prevention 472, 474
protease inhibitors, hepatitis C (HCV PI) 64–65
in HIV/HCV co-infection 86, 87, 87, 89
resistance avoidance 87
stop rules 65, 67
rashes, hepatitis C treatment side-effect 73
protein–energy malnutrition (PEM) 344
see also malnutrition
protein restriction 349
pruritus
hepatitis C treatment side-effect 72
in neonatal cholestasis, treatment 380
in primary biliary cirrhosis 153
management 156, 158
psychiatric patients, hepatitis C treatment 75
PTC (percutaneous transhepatic cholangiography) 116
pulmonary emboli, recurrent 257
pulmonary hypertension, portal hypertension and see portopulmonary hypertension (PPHTN)
PVS (peritoneovenous shunt), refractory ascites treatment 222
pyogenic liver abscess 104–110, 325
protein restriction 349
protein–energy malnutrition (PEM) 344
psychiatric patients, hepatitis C treatment 75
prothrombin time (PT)
PVS (peritoneovenous shunt), refractory ascites
quality of life, post-liver transplantation 534
recurrent disease, post-liver transplantation 437, 521–529
in children 528
complications, prevention/management 527
definition 521
diagnosis 440, 446, 455, 524–526
algorithm 526
differential 524
potential pitfalls/common errors 526
economic impact 522
hepatitis C 513
in elderly 528
hepatitis C see hepatitis C recurrence, post-liver transplantation
indications for hospitalization 527
in pregnancy 528
prevention 523–524
prognosis 528–529
treatment 526–527, 527
algorithm 528
refractory ascites 216, 216
prognosis 225
treatment 218, 222–223, 224
rejection activity index (RAI) 447
relapsing hepatitis A infection 39
renal dysfunction
in end-stage liver disease 428
post-liver transplantation 532
incidence 532
management 429–430, 532
risk factors 531, 532
in spontaneous bacterial peritonitis 231, 233
see also hepatorenal syndrome (HRS)
renal failure, in acute liver failure 282
treatment 288
reperfusion, ischemia–reperfusion injury pathogenesis 470
respiratory system
in end-stage liver disease 428
see also portopulmonary hypertension (PPHTN)
post-operative care of liver transplant patients 429
see also entries beginning pulmonary
re-transplantation see liver re-transplantation
ribavirin therapy
hepatitis C 64, 71, 73
adherence 68
effect on prognosis 75, 76
genotype 1 HCV 64–65, 66, 71
genotypes 2 and 3 HCV 65, 71, 74
genotypes 4, 5 and 6 HCV 65
in HIV-infected patients 86, 87, 89, 90, 91
recurrent, post-liver transplantation 516, 517
response, IL28B genotype and 70
treatment-experienced patients 66
see also hepatitis C treatment
treatment side-effects 67–68
management 71–72
teratogenicity 67–68, 72, 93
rifaxim therapy, hepatic encephalopathy 240, 240–241, 241, 242, 243
right heart catheterization, portopulmonary hypertension 266, 267
ROS (reactive oxygen species), ischemia–reperfusion injury pathogenesis 471
Roter syndrome 8
SAAG (serum–ascites albumin gradient) 213, 213, 216, 217
salt restriction see sodium restriction
sarcoidosis
diagnosis 153
non-cirrhotic portal hypertension in 314
sclerotherapy, portal hypertensive bleeding 201, 202, 202, 204
in children 386
evidence 207
screening
alcohol abuse 122, 124
alpha-1 antitrypsin deficiency 189
ascites 211, 212
Budd–Chiari syndrome 296
hepatitis B see hepatitis B, screening
hepatitis C see hepatitis C, screening
hepatocellular carcinoma see hepatocellular carcinoma (HCC)
hepatopulmonary syndrome 256
hepatorenal syndrome 247
hereditary hemochromatosis 169
liver disease in patients presenting for surgery 336
Index

screening (cont’d)
liver lesions 318
liver transplant recipients
  acute rejection 445, 454
  biliary complications 488
  general medical conditions 531
  infections 495
  post-liver transplantation malignancy 506, 506
  malnutrition 346
  neonatal cholestasis 375
  non-alcoholic fatty liver disease 134
  non-cirrhotic portal hypertension 309
  portal hypertensive bleeding 198
  portal vein thrombosis 302
  portopulmonary hypertension 161
  spontaneous bacterial peritonitis 228
  Wilson disease 229
  liver segments, liver 398–399
  sepsis
    in acute liver failure 282
    treatment 287
  diagnosis 355
  post-liver transplantation 446, 472
serological tests
  acute liver failure 286
  in children 357
  autoimmune disease 17
    autoimmune hepatitis 146, 147
    primary biliary cirrhosis 152, 154, 155
    primary sclerosing cholangitis 163, 163
  viral hepatitis 17
    hepatitis A/E 37
    hepatitis B 43–44, 44, 45
    hepatitis C 62, 63
SERPINA1 gene mutation 187, 188
serum–ascites albumin gradient (SAAG) 213, 213
SFSS (small for size syndrome) 399, 417, 464
shunt fraction, hepatopulmonary syndrome 257, 258, 259
sildenafil therapy, portopulmonary hypertension 268
silymarin 71
simple hepatic cysts 317
  diagnosis 326–327
  etiology 326
  imaging 326–327, 331
  incidence/prevalence 317, 325
  treatment 328, 329
  see also hepatic cysts
sirolimus therapy, liver transplant recipients
  acute rejection treatment 449
  chronic rejection treatment 458
  complications, prevention/management 458
  prevention of post-transplantation malignancy 506, 507, 508
SIRS (systemic inflammatory response syndrome) 252
skin cancer, post-liver transplantation 505, 507
  screening 506
small for size syndrome (SFSS) 399, 417, 464
smoking cessation, alpha-1 antitrypsin deficiency
  management 192, 193
sodium restriction, ascites treatment 218, 218, 345, 349
  in children 386
somatostatin analogues
  portal hypertensive bleeding treatment 201, 202
  in children 386
  see also octreotide therapy
spirinther of Oddi dysfunction, post-liver transplantation 486, 487, 488
spirometry, in alpha-1 antitrypsin deficiency 191
spironolactone therapy, ascites
  in cirrhotic 218, 219, 219, 220, 221
spontaneous bacterial peritonitis (SBP) 227–234
  in children 386–387
  clinical presentation 230
  definition 227
  diagnosis 229–231
  in children 386
  clinical 230
  differential 229
  laboratory 215, 230
  potential pitfalls/common errors 231
epidemiology 227
etiology 227–228, 386
  guidelines 234
  imaging techniques 231
  pathogenesis 228
  prevention 228–229
  in children 387
  prognosis 233
  risk factors 228
  screening 228
  treatment 231–232
    algorithm 232
    in children 386
    effect on prognosis 233
  steatohepatitis, non-alcoholic see non-alcoholic steatohepatitis
  steatosis, hepatic see hepatic steatosis
subjective global assessment (SGA) 347
substance abusers, hepatitis C treatment 75
surgery, in patients with liver disease 334–343
  contraindications 339, 342
  decision to proceed with 339, 339, 341
  disease severity classification 334, 336, 338
  effect on morbidity and mortality 334, 337, 340
  evidence 343
  follow-up tests and monitoring 342
  incidence/prevalence 334
  pathology/pathogenesis 335
  predictive/risk factors for decompensation after 335
  pre-operative assessment 336–338
    algorithm for patients with known liver disease 340
    algorithm for patients with suspected liver disease 337
    clinical 336–337
    imaging techniques 339
    laboratory 338–339
    potential pitfalls/common errors 339
    prevention/management of complications 341
    prognosis 342
    risks 335
    screening 336
  special populations 342
  surgical site infections, liver transplant recipients 497–498, 501
Swansea diagnostic criteria, acute fatty liver of pregnancy 274–275
systemic inflammatory response syndrome (SIRS) 252
Index 561

tacrolimus therapy, liver transplant recipients 433, 433
acute rejection treatment 449
chronic rejection treatment 458
complications, prevention/management 458
technetium-labeled macroaggregated albumin scan, hepatopulmonary syndrome diagnosis 259, 259
telaprevir therapy
hepatitis C 65, 67
see also protease inhibitors, hepatitis C (HCV PI)
telbivudine therapy, hepatitis B infection 46, 46
resistance 49
Tennessee system, HELLP syndrome classification 274
tenofivir therapy, hepatitis B infection 46, 46, 47
resistance 49
teratogenicity, ribavirin 67–68, 72, 93
terlipressin therapy, hepatorenal syndrome 250–251, 391
thiazolidinediones, non-alcoholic steatohepatitis management 138
thrombocytopenia
in acute liver failure 285
hepatitis C treatment side-effect 68, 73
thrombolytic therapy
Budd–Chiari syndrome 298, 298, 299
portal vein thrombosis 305, 305, 306
thrombosis
hepatic artery see hepatic artery thrombosis
portal vein see portal vein thrombosis
thrombotic thrombocytopenic purpura 273
thymoglobulin therapy, acute rejection 449
thyroid-stimulating hormone (TSH) abnormalities, hepatitis C treatment side-effect 68
TIPS see transjugular intrahepatic portosystemic shunting (TIPS)
tissue oxygen debt, in acute liver failure 282
treatment 287–288
tissue plasminogen activator, Budd–Chiari syndrome treatment 298, 298
Tokyo Guidelines 114, 114–115
tolvaptan therapy, cirrhotic ascites 221
torsemide therapy, cirrhotic ascites 219, 220
total bilirubin 4
level in jaundice 13
infants 377
see also bilirubin
taxins, acute liver failure etiologies 281
transferrin saturation, in hereditary hemochromatosis 169, 170
transjugular intrahepatic portosystemic shunting (TIPS)
Budd–Chiari syndrome 298, 298, 299, 299
hepatorenal syndrome 251
portal hypertensive bleeding 198–199, 201, 202, 204
in children 386
portal vein thrombosis 305, 305, 306
refractory ascites 222–223
transplantation, liver see liver transplantation (LT)
triamterene therapy, cirrhotic ascites 220
trientine, Wilson disease treatment 182, 183, 184
triglycerides, ascitic fluid 216
tuberculosis, peritoneal 229
tyrosinemia 361
ultrasonography
amebic liver abscess 100
ascites 216
hepatitis C 62
hepatorenal syndrome 249
jaundiced patients 17–18
infants 377
non-alcoholic fatty liver disease 136
post-liver transplantation 431
pyogenic liver abscess 106
see also imaging techniques
United Network for Organ Sharing (UNOS) Criteria for Status I Listing 289
University of California San Francisco (UCSF) criteria 409
urinary tract infections, post-liver transplantation 498–499, 502
urine copper levels, in Wilson disease 180
urokinase therapy, Budd–Chiari syndrome 298, 298
ursodeoxycholic acid (UDCA)
inhaepatic cholestasis of pregnancy treatment 276, 277
primary biliary cirrhosis treatment 155, 156, 156, 157
primary sclerosing cholangitis treatment 164, 164
vaccinations
in alpha-1 antitrypsin deficiency 193
hepatitis A 33, 34, 34
hepatitis B see hepatitis B vaccination
post-liver transplantation 534–535
pre-liver transplantation 496
Vancouver Forum Criteria, live liver donation 415–416
variceal bleeding see portal hypertensive bleeding
vascular complications, post-liver transplantation 431–432, 477–485
hepatic artery thrombosis see hepatic artery thrombosis, post-liver transplantation
hepatic venous occlusion see hepatic venous occlusion, post-liver transplantation
portal vein thrombosis see portal vein thrombosis, post-liver transplantation
vascular liver disorders
acute liver failure etiologies 281
diagnosis 26, 35
see also specific disorders
vasopressin receptor antagonists, cirrhotic ascites treatment 221
viral hepatitis
acute liver failure etiologies 281, 281
diagnosis 25, 123, 134, 190, 296
treatment 288
see also specific types
viral infections
acute liver failure etiologies 281
post-liver transplantation 499
prophylaxis 496
see also infections, post-liver transplantation
viral rebound, definition 49
viral resistance
detection methods 49
nomenclature 48–49
virologic breakthrough, definition 49
vitamin deficiency
in children 388
findings 348
screening 346
see also malnutrition
vitamin E supplementation
in children with chronic liver disease 391
in non-alcoholic steatohepatitis 138
vitamin K deficiency 348, 355
vitamin supplementation
  in children with chronic liver disease 389, 390–391
  in hepatitis C 71
  in HIV/HCV co-infected patients 89
  in neonatal cholestasis 380
  in primary biliary cirrhosis 156

warm ischemia
  liver graft 464, 470
  see also ischemia–reperfusion injury

weight gain, post-liver transplantation 533

West Haven Criteria (WHC) 237

WHO classification, post-transplant lymphoproliferative disorder 400

Wilson disease 176–186
  associated conditions 181
  clinical presentation 179, 289
  definition 176
  diagnosis 9, 61, 134, 145, 179–182
    algorithm 181
  clinical 179
  differential 179, 273
  imaging techniques 181
  laboratory 7, 180, 285, 286
  pathological features on liver biopsy 180–181
  potential pitfalls/common errors 182
  economic impact 176
  etiology 177
  follow-up tests and monitoring 185
  guidelines 186
  indications for hospitalization 182
  Kayser–Fleischer rings 177, 179, 180, 181, 186
  pathophysiology 177
  predictive/risk factors 177
  prevalence 176
  prevention 177
  prognosis 185
  screening 177
    algorithm 178
  treatment 182–183, 183, 289
    algorithm 184
  complications, prevention/management 183
  effect on prognosis 185
  special populations 184–185
  zinc therapy, Wilson disease 182, 183, 183, 184–185, 184